Phase 1 study assesses CP-751,871 with docetaxel in advanced non-hematologic malignancies
Background
Treating non-hematologic malignancies (solid tumors) presents significant challenges, often due to resistance to conventional therapies and dose-limiting toxicities. Docetaxel, a widely used chemotherapy agent, is effective in various solid tumors but its utility is constrained by these factors. The insulin-like growth factor 1 receptor (IGF-1R) pathway is a crucial driver of cancer cell proliferation, survival, and resistance to apoptosis, making it an attractive therapeutic target. By combining docetaxel with a targeted agent like CP-751,871, an IGF-1R antibody, researchers aim to overcome existing treatment limitations and potentially enhance therapeutic outcomes.
Study Design
This was a Phase 1, open-label, dose-escalation clinical trial designed to investigate the combination of CP-751,871 and docetaxel. The study enrolled patients with advanced non-hematologic malignancies for whom docetaxel was considered a suitable treatment option. The primary objectives were to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of escalating doses of CP-751,871 when administered alongside docetaxel. Key endpoints included assessing dose-limiting toxicities (DLTs), characterizing adverse events (AEs), and profiling the PK and PD of the combination to establish a recommended Phase 2 dose.
Results
The provided abstract describes the design and objectives of this clinical trial but does not report any specific findings or results. The study was established to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CP-751,871 in combination with docetaxel in patients with advanced non-hematologic malignancies. No numerical data, p-values, or statistical outcomes regarding efficacy, specific adverse event rates, or dose-limiting toxicities are presented in this abstract. Therefore, no concrete findings can be extracted or reported from this description, as the study's results are not yet detailed.
Why It Matters
Combining targeted therapies with traditional chemotherapy represents a promising strategy to improve patient outcomes in advanced non-hematologic malignancies. If CP-751,871 can safely enhance docetaxel's efficacy by inhibiting the IGF-1R pathway, it could offer a novel approach to overcome chemotherapy resistance and improve survival. This Phase 1 study is critical for establishing a safe and tolerable dosing regimen for this combination, which is an essential prerequisite for advancing to larger efficacy trials. Understanding the pharmacokinetics and pharmacodynamics of this dual-agent approach will be vital for optimizing future clinical protocols and identifying patient populations most likely to benefit.
cp-751,871
docetaxel
non-hematologic-malignancies
solid-tumors
phase-1
clinical-trial